827025-41-2

Basic information

• Product Name: BENZOIC ACID, 3-[[2-[(METHYLAMINO)CARBONYL]-4-PYRIDINYL]OXY]-
• Synonyms: 3-(2-METHYLCARBAMOYL-PYRIDIN-4-YLOXY)-BENZOIC ACID;BENZOIC ACID, 3-[[2-[(METHYLAMINO)CARBONYL]-4-PYRIDINYL]OXY]-;3-[[2-[(Methylamino)carbonyl]-4-pyridinyl]oxy]benzoic acid
• CAS NO: 827025-41-2
• Molecular Formula: C₁₄H₁₂N₂O₄
• Molecular Weight: 272.259
• Mol File: 827025-41-2.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: BENZOIC ACID, 3-[[2-[(METHYLAMINO)CARBONYL]-4-PYRIDINYL]OXY]-(CAS DataBase Reference)
• NIST Chemistry Reference: BENZOIC ACID, 3-[[2-[(METHYLAMINO)CARBONYL]-4-PYRIDINYL]OXY]-(827025-41-2)
• EPA Substance Registry System: BENZOIC ACID, 3-[[2-[(METHYLAMINO)CARBONYL]-4-PYRIDINYL]OXY]-(827025-41-2)

Safety Data

• Hazardous Substances Data: 827025-41-2(Hazardous Substances Data)

Upstream product

• 827025-40-1 3-(2-methylcarbamoyl-pyridine-4-yloxy)-benzoic acid ethyl ester 
• 864291-32-7 3-(2-methylcarbamoyl-pyridin-4-yloxy)-benzoic acid methyl ester 

Downstream Products

• 856424-02-7 3-(2-methylcarbamoyl-pyridine-4-yloxy)-benzoic acid pentafluoro-phenyl ester 

Relevant articles and documents

PYRIDINAMIDE DERIVATIVE AS KINASE INHIBITORS

The invention relates to substituted arylamide derivatives of formula (I), to the production and use thereof for the production of a medicament for the treatment of diseases, in particular tumours and/or diseases which are provoked, transmitted and/or propagated by angiogenesis. Compounds of formula (I) are active inhibitors of tyrosine kinases, in particular TIE-2 and VEGFR, and the Raf-kinases.

BENZIMIDAZOLE DERIVATIVES AS RAF KINASE INHIBITORS

The present invention relates to benzimidazole derivatives of formula I, the use of the compounds of formula I as inhibitors of one or more kinases, the use of the compounds of formula I for the manufacture of a pharmaceutical composition and a method of treatment, comprising administering said pharmaceutical composition to a patient. Accordingly, the compound of Formula I or a pharmaceutically acceptable salt thereof is administered for the treatment of diseases mediated by one or more kinase pathways, preferably by the raf kinase pathway, especially cancers, [FORMULA]